CAR T-Cell Therapy in Multiple Myeloma

home / from-all-angles / car-t-cell-therapy-in-multiple-myeloma

Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy is transforming the treatment of relapsed/refractory multiple myeloma, highlighting the decision-making process, patient preparation, management of adverse effects, and the importance of multidisciplinary collaboration to optimize outcomes and improve quality of life.

EP. 1: Navigating the Myeloma Journey: Insights from Diagnosis to First-Line Treatment in Standard-Risk Patient

Omar Castaneda Puglianini, MD ;Jammie Freeman, RN ;Raja Assal

December 5th 2024

Panelists discuss how the patient’s journey with multiple myeloma begins with an initial diagnosis followed by first-line treatments and how this informs the decision to consider chimeric antigen receptor T-cell therapy as a subsequent option in their treatment path.

EP. 2: Exploring CAR-T Therapy: Discussing Its Introduction and Shared Decision-Making in Myeloma Treatment

Omar Castaneda Puglianini, MD ;Jammie Freeman, RN ;Raja Assal

December 6th 2024